Somatostatin, release inhibitor hormone or factor, was first isolated from hypothalamic extracts by Guillemin and Gerich1 in 1972. As is illustrated in Altman and associates' work,2 published in this issue of the Archives, this hormone and its analogues may be useful in treating a variety of diseases caused by the excess of certain hormones and mediators of inflammation. The 14-amino acid peptide was subsequently identified in pancreas (D cells of the islets of Langerhans), stomach, small intestine, and throughout the central and peripheral nervous systems. The amino acid sequence of somatostatin and its synthesis in the laboratory were quickly followed by many pharmacologic and physiologic studies, which revealed that somatostatin has many actions in addition to inhibiting the secretion of growth hormone (Table 1).3
The original authors recognized that somatostatin might have clinical applications in the management of acromegaly and juvenile diabetes. However, several undesirable characteristics
Camisa C. Somatostatin and a Long-Acting Analogue, Octreotide Acetate: Relevance to Dermatology. Arch Dermatol. 1989;125(3):407–412. doi:10.1001/archderm.1989.01670150097017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: